Why the study?
Current ESC guidelines recommend a stepwise approach to dyslipidemia after ACS, whereas recent evidence highlights the benefits of systematic, early combination therapy for faster and more consistent LDL-C reductions. This project implemented a shared workflow to ensure uniform treatment strategies across a single department.
Does a structured shared workflow for early, tailored combination lipid-lowering therapy improve LDL-C target achievement at one month in patients with acute coronary syndrome?
Cohort (n=105)
No
Does a structured shared workflow for early, tailored combination lipid-lowering therapy improve LDL-C target achievement at one month in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Implementing a structured workflow for early combination lipid-lowering therapy in ACS patients markedly increases dual and triple therapy prescription at discharge and enables 70.6% of followed patients to reach stringent LDL-C targets within one month.
Background The management of dyslipidemia is a cornerstone of secondary prevention in acute coronary syndrome (ACS). Current ESC Guidelines recommend a stepwise approach, progressively adding therapies based on prior treatments and baseline LDL–C levels. However, recent evidence highlights the benefits of systematic, early combination therapy in achieving faster and more consistent LDL–C reductions, improving both acute and long–term outcomes. This project implemented a shared workflow to ensure uniform treatment strategies across our department. Methods From June to November 2024, ACS patients were consecutively enrolled and categorized as therapy–naïve or pretreated. No patients were identified as statin–intolerant. Therapy–naïve patients were stratified by cardiovascular risk, with extreme risk defined by multivessel disease, peripheral or cerebrovascular atherosclerosis, or recurrent vascular events. LDL–C goals were ‹55 mg/dL for very–high–risk patients and ‹40 mg/dL for extreme–risk patients. Naïve patients received high–intensity statins and ezetimibe, initiated before PCI. PCSK9 inhibitors were added when needed based on risk and baseline LDL–C. Pretreated patients had their therapies optimized through titration of statin intensity and/or the addition of ezetimibe or PCSK9 inhibitors. Results A total of 105 patients were included (mean LDL–C 96.6 mg/dL): 44 (42%) were pretreated, and 61 (58%) were therapy–naïve, including 26 at extreme risk. Statin monotherapy decreased from 28.6% at admission to 5.7% at discharge. Dual therapy increased from 12.4% to 79%, and triple therapy rose from 0.9% to 15.2%. At one–month follow–up (48.6% of patients), 70.6% achieved LDL–C targets (mean LDL–C: 40.5 mg/dL vs. 94.1 mg/dL at admission). Discussion This study supports the “Strike Early, Strike Strong” strategy, emphasizing early, intensive LDL–C lowering after ACS. The structured workflow allowed tailored, evidence–based management, achieving consistent LDL–C reductions. Challenges included limited follow–up data, regional restrictions on PCSK9 inhibitor prescriptions, and difficulties in monitoring adherence. Nevertheless, this initiative demonstrates the feasibility of applying uniform strategies to improve outcomes, providing a replicable model for other centers. Conclusion Despite limitations, this project highlights the importance of structured workflows in ACS management, paving the way for future studies on long–term outcomes.
No takes yet. Share an insight, caveat, or question.
Zambelli et al. (2025) conducted a cohort in Acute coronary syndrome (ACS) with dyslipidemia (n=105). Structured early combination lipid-lowering workflow (high-intensity statins, ezetimibe, and PCSK9 inhibitors as needed) vs. Baseline admission status was evaluated on Achievement of LDL-C targets (<55 mg/dL for very-high-risk and <40 mg/dL for extreme-risk patients) at 1-month follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: